


This listing of claims will replace all prior versions, and listings, of claims in the Application.

1-8 (cancelled)

9. (currently amended) The compound according to claim 8, of Formula IV.



IV

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H, -OR<sup>6</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -O-N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)OR<sup>6</sup>,

-N(R<sup>6</sup>)N(R<sup>6</sup>)R<sup>7</sup>, absent, oxo, thiono, and imino, with the proviso that when X is oxo,

thiono, or imino, there is only one  $R^1$ :

R<sup>1</sup> and R<sup>2</sup>, at each occurrence, are each independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclylalkyl;

optionally two of R<sup>2</sup> together are oxo;

optionally, at least one pair of substituents, selected from two of R<sup>1</sup>, two of R<sup>2</sup>, and one each of R<sup>1</sup> and R<sup>2</sup>, together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, when paired, together with the

corresponding atom or atoms of the first ring to which they are attached, form a second ring comprising between three and seven annular atoms, said second ring optionally substituted with between zero and three of R<sup>1</sup>;

R<sup>3</sup> is selected from -H, optionally substituted lower alkyl, optionally substituted lower arylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted alkoxy;

optionally R<sup>3</sup> and one of R<sup>2</sup>, together with the atoms to which each is attached, form a third ring comprising between three and seven annular atoms, said third ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the third ring to which they are attached, form a fourth ring comprising between three and seven annular atoms, said fourth ring optionally substituted with between zero and three of R<sup>1</sup>;

optionally R<sup>3</sup> and one of R<sup>1</sup>, together with the atoms to which they are attached and the carbon to which R<sup>2</sup> is attached, form a fifth ring comprising between three and seven annular atoms, said fifth ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the fifth ring to which they are attached, form a sixth ring comprising between three and seven annular atoms, said sixth ring optionally substituted with between zero and three of R<sup>1</sup>;

m is zero to four;

each of R<sup>4</sup> is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl;

each Y is independently either =C(R<sup>5</sup>)- or =N-, provided that there are no more than three of =N- in the aromatic ring bearing Y;

each Z is independently either =C(R<sup>4</sup>)- or =N-;

n is zero to five;


each R<sup>5</sup> is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R<sup>6</sup> is -H or R<sup>7</sup>;

R<sup>7</sup> is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and


R<sup>6</sup> and R<sup>7</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

10. (original) The compound according to claim 9, wherein X is selected from -OR<sup>6</sup>, -SR<sup>6</sup>, and -N(R<sup>6</sup>)R<sup>7</sup>.
11. (original) The compound according to claim 10, wherein two of R<sup>1</sup>, together with the carbon or carbons to which they are attached, form said second ring.
12. (original) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R<sup>1</sup>.
13. (original) The compound according to claim 12, of formula V.



V

14. (original) The compound according to claim 13, wherein X is -OR<sup>6</sup>.
15. (original) The compound according to claim 14, wherein R<sup>3</sup> is -H.
16. (original) The compound according to claim 15, wherein X is -OH.
17. (original) The compound according to claim 16, of formula VI.



VI

18. (original) The compound according to claim 17, wherein R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> are -H.
- 19-29. (cancelled)
30. (currently amended) ~~The A compound according to claim 1, selected from Table 3-3:~~

Table 3

#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4-amine	

Table 3







#	Name	Structure
2	<del>2-pyridin-4-yl-N-(2-pyrrolidin-1-ylethyl)quinazolin-4-amine</del>	
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4-amine	
4	N-(cyclohexylmethyl)-2-pyridin-4-ylquinazolin-4-amine	
5	<del>2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol</del>	
6	<del>3-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol</del>	
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4-ylquinazolin-4-amine	

Table 3







#	Name	Structure
8	<del>N,N dimethyl N'-(2-pyridin-4-ylquinazolin-4-yl)ethane-1,2-diamine</del>	
9	<del>N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin-4-ylquinazolin-4-amine</del>	
10	<del>N-(2-morpholin-4-ylethyl)-2-pyridin-4-ylquinazolin-4-amine</del>	
11	<del>4-[4-(2-pyridin-4-ylquinazolin-4-yl)piperazin-1-yl]phenol</del>	
12	<del>2-pyridin-4-yl-N-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine</del>	
13	<del>4-piperazin-1-yl-2-pyridin-4-ylquinazoline</del>	

Table 3






#	Name	Structure
14	<del>1,1 dimethylethyl 4-(2-pyridin-4-ylquinazolin-4-yl)piperazine-1-carboxylate</del>	
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	
16	4-[(1S)-2,3-dihydro-1H-inden-1-ylmethyl]-2-pyridin-4-ylquinazoline	
17	<del>(1R,2S)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	

Table 3

#	Name	Structure
19	1,1-dimethylethyl 4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperidine-1-carboxylate	
20	<del>2-pyridin-4-yl-N-[[2,4,6-tris(methoxy)phenyl]methyl]quinazolin-4-amine</del>	
21	<del>N-piperidin-4-yl-2-pyridin-4-ylquinazolin-4-amine</del>	
22	<del>N-((1S,2S)-2-[(phenylmethyl)oxy]cyclopentyl)-2-pyridin-4-ylquinazolin-4-amine</del>	
23	<del>N-phenyl-N'-(2-pyridin-4-ylquinazolin-4-yl)benzene-1,4-diamine</del>	



Table 3

#	Name	Structure
24	3-[(2-pyridin-4-ylquinazolin-4-yl)amino]naphthalen-2-ol	
25	N-{4-[(1-methylethyl)oxy]phenyl}-2-pyridin-4-ylquinazolin-4-amine	
26	<del>(1S,2R)-1-[(2-phenylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	
27	<del>(1R,2S)-1-[(2-phenylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	
28	<del>(1R,2R)-2-[(2-phenylquinazolin-4-yl)amino]cyclopentanol</del>	

Table 3

#	Name	Structure
29	(1R,2R)-2-[(2-phenylquinazolin-4-yl)amino]cyclohexanol	
30	(1S,2R,3R,5R)-3-(hydroxymethyl)-5-[(2-phenylquinazolin-4-yl)amino]cyclopentane-1,2-diol	
31	(1S,2R)-1-[(6-chloro-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
32	N-(2-piperazin-1-ylethyl)-2-pyridin-4-ylquinazolin-4-amine	
33	(1S,2R)-1-[(2-pyridin-3-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	

Table 3






#	Name	Structure
34	<del>(1R,2S)-1-[(2-pyridin-3-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	
35	<del>(1R,2R)-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]cyclopentanol</del>	
36	<del>(1R,2R)-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]cyclohexanol</del>	
37	<del>(1S,2R)-1-[(2-pyridin-2-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	
38	<del>(1R,2S)-1-[(2-pyridin-2-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	

Table 3

#	Name	Structure
39	(2S)-3-[(2-pyridin-4-ylquinazolin-4-yl)amino]propane-1,2-diol	
40	[(2S)-1-(2-pyridin-4-ylquinazolin-4-yl)-2,3-dihydro-1H-indol-2-yl]methanol	
41	(2R)-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	
42	(2S)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-2-ol	
43	(1S,2R)-1-[(2-(2-ethylpyridin-4-yl)quinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	

Table 3

#	Name	Structure
44	(1R,2S)-1-[[2-(2-ethylpyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
45	(1S,2R)-1-[(6-bromo-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
46	(1S,2R)-1-[[6,7-bis(methoxy)-2-pyridin-4-yl]quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
47	1-(2-pyridin-4-yl)quinazolin-4-yl]piperidin-3-ol	
48	(1S,2R)-1-[[2-(2-(trifluoromethyl)pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	

Table 3

#	Name	Structure
49	(1S,2R)-1-((2-[6-(methyloxy)pyridin-3-yl]quinazolin-4-yl)amino)-2,3-dihydro-1H-inden-2-ol	
50	N-[(3S)-piperidin-3-yl]-2-pyridin-4-ylquinazolin-4-amine	
51	(1S,2R)-1-[(7-methyl-2-pyridin-4-yl]quinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
52	<del>(1S,2R)-1-((2-[2,4-bis(methyloxy)pyrimidin-5-yl]quinazolin-4-yl)amino)-2,3-dihydro-1H-inden-2-ol</del>	
53	<del>(2R)-3-methyl-2-[(2-pyridin-4-yl]quinazolin-4-yl)amino]butan-1-ol</del>	

Table 3

#	Name	Structure
54	(2S)-3-methyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]butan-1-ol	
55	(2S)-2-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
56	(2R)-2-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
57	(1S,2R)-1-[(2-pyridin-4-ylpyrimidin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
58	<del>(1S,2R)-1-[(2-pyrazin-2-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol</del>	
59	<del>(1S,2R)-1-[[2-(4-aminopyridin-3-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol</del>	

Table 3









#	Name	Structure
60	(2R)-3-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	
61	(2S)-3-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	
62	2-[(phenylmethyl)(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
63	(1S,2R)-1-[[2-(2-aminopyrimidin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
64	<del>5-(1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino)quinazolin-2-yl)pyridin-2-ol</del>	



Table 3

#	Name	Structure
65	<del>(1S,2R) 1-((2-[2-(methylthio)pyrimidin-4-yl]quinazolin-4-yl)amino)-2,3-dihydro-1H-inden-2-ol</del>	
66	2-{4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperazin-1-yl}ethanol	
67	N-piperidin-1-yl-2-pyridin-4-ylquinazolin-4-amine	

31. (currently amended) A pharmaceutical composition comprising the compound according to ~~any one of claims 1-31~~ 9 and a pharmaceutically acceptable carrier.

32. (currently amended) A metabolite of the compound or the pharmaceutical composition according to ~~any one of claims 1-31~~ 9.

33-38. (cancelled)